Challenges of Diagnosing MSA vs. PD

A man performing Alzheimer's disease research

SYNTap Test Capabilities

This biomarker test can detect α-Synuclein with 87% sensitivity, 97% specificity, and 93.9% accuracy.

Specification Sheet

SYNTap Spec Sheet - Disease Lead

The diagnosis of MSA vs. PD represents a major challenge particularly in early stages of the disease due to overlapping symptoms.

There are indications that SYNTap Test can be useful as a diagnostic test for MSA vs. PD. We are working towards a clinical validation and actively looking to partner in this project.

“The α-synuclein-PMCA assay (SAA) can discriminate between samples of cerebrospinal fluid from patients diagnosed with Parkinson's disease and samples from patients with multiple system atrophy, with an overall sensitivity of 95.4%.”  (Ref.10)

Research Partnership

Amprion continues to research the role of the SYNTap Test in contributing to the diagnosis and as part of the treatment decision making for several neurodegenerative diseases.

We are actively looking for partners to accelerate diagnostics and treatment innovations. 

To explore potential collaboration, please email us:

Download the SYNTap Test Specification Sheet for details.

Please Note: Important Billing Info

To improve patient access to the SYNTap® Biomarker CSF Test, Amprion offers the following billing options:

  • List price of $1500, with courtesy billing for both Medicare and private insurance.
  • An affordable self-pay price of $995 (patients may qualify for financial assistance and/or interest-free payment options).
  • Prices are effective as of January 1, 2024, and are subject to change.

Please note: Amprion is a Medicare participating provider, however, the SYNTap test does not currently have Medicare coverage determination. Also, Amprion is not yet in network with most insurers.

The SYNTap Biomarker CSF Test has been issued a dedicated CPT® PLA code to be used when billing: 0393U.

For additional information, please visit our billing page.